RE:RE:920 K 920 K 920 Freaking Thousand lscfa wrote: I bet the legal fees are for Nasdaq prep work. Gagnon is delusional. Poet Technologies did a 1-for-10 rollback to list on Nasdaq. The stock has gone from $15.00 to .90 with delays in product launches.
Poet had a $500 million market cap. CZO has a $20 million market cap.
Even if CZO's base business comes back, which is expected, the stock could double. CZO is also working on other products for launch(powders, avenanthramide malted technology for neutraceuticals) and is examining other sources of revenue perhaps. In the past Gilles has talked about a PGX partnership with a NASDAQ listing and PGX is being scaled up right now; including to commercial scale by September 20224. CZO produced blowout bioavailability results vs. the gold standard for CoQ10 and Gilles said it's a $4 billion market. He said CZO was in talks with serious companies who understand bioavailability as a unique selling point. CZO may have found a way to hijack macrophages to deliver CoQ10 as a booster beyond PGX delivery. It may have a Trojan Horse for the delivery of a number of drugs. CZO has designed an animal study for a head-to-head immune booster trail and yeast beta glucan is a $1 billion market in a much broader immune booster market. CZO may have the gold standard. Avalyn raised C$80 million going into its Phase I fibrosis trial and CZO is completing a short toxicology study ahead of a potential filing. CZO's avenanthramide pill clinical trial will start producing data next week. The wound healing applications have already passed the gold standard model other companies use.
That CZO is confidently spending material money, time, and resources on legal fees and wants on the biggest stage(NASDAQ) ahead of key catalysts speaks to the confidence it has in the path forward. It's time to go big! And interest rates appear to have topped potentially meanng a new bull market in biotech.
"Further, over the past quarter we remained very active with strategic corporate initiatives aimed towards achieving a stated objective related to uplisting Ceapro to an international stock exchange." news release